Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cryo-Cell InternationalCCEL +10.54%60 EV-to-OCF is 5.87 as of Aug. 13, 2026, which is 31% below its 10-year median of 8.46. GuruFocus rates CCEL with a GF Score™ of 60/100 and a GF Value™ of $5.55 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Cryo-Cell International ranks better than 61.49% on this metric.
The historical rank and industry rank for Cryo-Cell International's EV-to-OCF or its related term are showing as below:
CCEL'
s EV-to-OCF Range Over the Past 10 Years
Min: 3.94 Med: 8.46 Max: 14.32
Current: 5.87
During the past 13 years, the highest EV-to-OCF of Cryo-Cell International was 14.32. The lowest was 3.94. And the median was 8.46.
CCEL's EV-to-OCF is ranked better than 61.49% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 8.91
vs CCEL: 5.87
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cryo-Cell International (AMEX:CCEL) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cryo-Cell International's PE Ratio (TTM) for today is calculated as:
Cryo-Cell International's share price for today is $3.88.
Cryo-Cell International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.300.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Cryo-Cell International's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International EV-to-OCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's EV-to-OCF falls into.
Cryo-Cell International's current Enterprise Value is $37.08 Mil.
Cryo-Cell International's Cash Flow from Operations for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International (CCEL) has a EV-to-OCF of 5.87 as of Aug. 13, 2026. This is 31% below median its historical median of 8.46. Over the past decade, Cryo-Cell International's EV-to-OCF has ranged from 3.94 to 14.32. According to the industry distribution chart, Cryo-Cell International ranks #263 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 38.5%.
Is Cryo-Cell International's EV-to-OCF too high?
Cryo-Cell International's current EV-to-OCF of 5.87 is 31% below median its 10-year median of 8.46. Over the past 10 years, this metric has ranged from a low of 3.94 to a high of 14.32. The Healthcare Providers & Services industry median EV-to-OCF is 8.91. Cryo-Cell International's value of 5.87 is 34.1% below this industry median. Based on the distribution chart, Cryo-Cell International ranks #263 out of 683 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Cryo-Cell International has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's EV-to-OCF compare to EHSI and PIII?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #263 out of 683 companies for EV-to-OCF. This puts Cryo-Cell International in the upper half of its industry. The industry median EV-to-OCF is 8.91. Cryo-Cell International's value of 5.87 is 34.1% below this benchmark. Historically, Cryo-Cell International's own EV-to-OCF has ranged from 3.94 to 14.32 over the past decade. While the company's 10-year median is 8.46 vs. the industry median of 8.91, Cryo-Cell International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Healthcare Providers & Services company?
The median EV-to-OCF among Healthcare Providers & Services companies is 8.91, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current EV-to-OCF of 5.87 is 34.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median EV-to-OCF is 8.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current EV-to-OCF is 5.87, which is 31% below median its own 10-year median of 8.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (CCEL) is currently considered Possible Value Trap. The stock's GF Value™ is $5.55, compared to a current price of $3.88 — trading 30.1% below its estimated fair value. The current EV-to-OCF is 5.87, which is 31% below median its 10-year median of 8.46 and 34.1% below the Healthcare Providers & Services industry median of 8.91. Cryo-Cell International's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cryo-Cell International (CCEL), the current EV-to-OCF is 5.87 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (CCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of $3.88 is trading 30.1% below its estimated GF Value™ of $5.55.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for CCEL:
EV-to-OCF: 5.87 (31% below median its 10-year median of 8.46)
GF Value™: $5.55 vs. price of $3.88 (30.1% below fair value)
Industry Position: 34.1% below the Healthcare Providers & Services median (#263 of 683)
No single metric tells the full story. See the CCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
60GF Score
Get the complete analysis for CCEL
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CCEL has been successfully added to your 
